2025-09-06 - Analysis Report
Okay, here's a report analyzing RXRX (Recursion Pharmaceuticals Inc.) based on the data you provided.

## RXRX (Recursion Pharmaceuticals Inc.) Analysis

**Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI to discover, develop, and commercialize novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (RXRX):** -47.08%
*   **Cumulative Return (VOO):** 40.41%
*   **Absolute Divergence:** -87.49% (RXRX underperformed VOO by this amount)
*   **Divergence Range:**
    *   Max: 35.8
    *   Min: -89.0
    *   Current: -85.4
    *   Relative Divergence: 2.9

**Analysis:** RXRX has significantly underperformed the S&P 500 over the observed period. The relative divergence of 2.9 indicates that the current underperformance is near the extreme lower end of its historical range.

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2021-2023  | 5.0%   | 73.6%  | -1.0%  | -0.1  | 4.3    |
| 2022-2024  | 0.0%   | 73.6%  | -25.0% | 0.1   | 3.0    |
| 2023-2025  | 4.0%   | 73.6%  | -49.0% | 0.1   | 2.0    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) is relatively low across all periods, indicating weak overall growth.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high (73.6%), suggesting substantial risk and volatility in the stock's price.
*   **Alpha:** The negative Alpha values indicate that RXRX has consistently underperformed its benchmark on a risk-adjusted basis. The negative alpha is worsening over time.
*   **Beta:** The Beta values are close to zero, suggesting that RXRX's price is not highly correlated with the overall market (S&P 500).
*   **Cap(B):** The market capitalization is decreasing from 4.3B to 2.0B over time.

### 2. Recent Price Action

*   **Current Price:** 4.61
*   **Previous Close:** 4.52
*   **Change:** 1.99%
*   **5-Day Moving Average:** 4.614
*   **20-Day Moving Average:** 5.0377
*   **60-Day Moving Average:** 5.345

**Analysis:** The stock price saw a recent increase (+1.99%), closing at 4.61. However, the price remains below the 20-day and 60-day moving averages, which might suggest a short-term upward correction within a longer-term downtrend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3322 (Low Risk)
*   **RSI:** 18.48 (Oversold)
*   **PPO:** -0.9388
*   **Hybrid Signal:** Cash_70%_Sell (70% of holdings)
*   **Recent (20-day) Relative Divergence Change:** 2.1 (+) - Short-term increase
*   **Expected Return (%):** -891.4

**Analysis:**

*   The MRI suggests a low market risk environment, which is contradictory to the very negative returns and high drawdown.
*   The RSI is very low, indicating an oversold condition, which could signal a potential bounce or reversal.
*   The Hybrid Signal recommends selling 70% of holdings and increasing cash position to 70%, based on the algorithm's risk assessment.
*   The recent increase in relative divergence suggests some short-term positive momentum.
*   The extremely negative expected return (-891.4%) indicates a very pessimistic outlook for long-term returns compared to the S&P 500.
*   The significant price change compared to the previous close suggests a volatile move, which needs to be considered in light of recent news and market sentiment.

### 4. Recent News & Significant Events

*   **[2025-09-03]** Rallybio Receives $12.5 Million Equity Milestone From Recursion
*   **[2025-08-29]** If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
*   **[2025-08-28]** Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition
*   **[2025-08-28]** 1 Monster Nvidia-Backed Artificial Intelligence (AI) Data Center Stock To Buy Hand Over Fist Before It Soars 20%, According to a Wall Street Analyst
*   **[2025-08-27]** Recursion to Participate in Upcoming Investor Conferences
*   **[2025-08-25]** 1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell

**Analysis:**

*   The news is mixed. The Rallybio milestone payment is positive, and the pipeline expansion through the REV102 acquisition could be seen as a positive strategic move.
*   However, articles highlighting past investment performance ("If You'd Invested...") and the "Reasons to Sell" article suggest concerns about the company's current standing.
*   The article mentioning Nvidia and AI is relevant, given Recursion's focus on AI in drug discovery. If the company is perceived as benefiting from the AI boom, it could attract investor interest.
*   Participation in investor conferences is generally a positive sign, as it indicates the company's willingness to communicate its strategy and progress to the market.

### 4-2. Analyst Opinions

*   **Consensus:** None
*   **Mean Rating:** -
*   **Opinions:** 6
*   **Target Price (avg/high/low):** 6.47 / 10.00 / 3.00
*   **Recent Rating Changes:** No recent changes indicated.

**Analysis:** The analyst target prices suggest a potential upside from the current price, with an average target of $6.47. However, the lack of recent rating changes may indicate that analysts are taking a "wait and see" approach.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-08-05 | -0.41 | 0.02 B$   |
| 2025-05-05 | -0.5  | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2024-08-08 | -0.4  | 0.01 B$   |
| 2025-08-05 | -0.4  | 0.01 B$   |

**Analysis:** The company is consistently reporting negative EPS, indicating a lack of profitability. Revenue is fluctuating but generally low. This underscores the company's position as a growth-stage company that is still investing heavily in R&D.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.02B    | -5.54%        |
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |
| 2024-06-30 | $0.01B    | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $0.92B    | -18.70%   |
| 2025-03-31 | $0.93B    | -21.68%   |
| 2024-12-31 | $1.03B    | -17.29%   |
| 2024-09-30 | $0.52B    | -18.27%   |
| 2024-06-30 | $0.58B    | -16.69%   |

**Analysis:**

*   Revenue is variable, with some quarters showing significant declines.
*   Profit margins are generally negative, with a few exceptions. The negative margins and inconsistent revenue highlight the challenges in achieving profitability.
*   Equity has fluctuated, and ROE is consistently negative, reflecting the company's inability to generate profits from its equity base.

### 7. Overall Assessment

RXRX is a high-risk, high-potential play in the AI-driven drug discovery space.

*   **Negatives:** Significant underperformance compared to the S&P 500, negative EPS, volatile revenue, negative profit margins, and a very pessimistic expected return.
*   **Positives:**  Oversold RSI suggesting a potential bounce, potential upside based on analyst target prices, and news of pipeline expansion and AI-related developments. The low MRI score also suggests low market risk.

**Conclusion:**

The data suggests that RXRX is currently facing significant challenges. While there are some potentially positive catalysts, the overall picture is concerning. Investors should carefully weigh the risks and potential rewards before considering an investment in RXRX. The Hybrid Signal's recommendation to reduce holdings and increase cash position is a cautious signal.  It appears the recent price increase may be a temporary fluctuation within a broader downtrend. Further monitoring of earnings, pipeline progress, and market sentiment is essential.
